Jakarta, CNBC Indonesia – President French Emmanuel Macron warns about the Chinese vaccine. He said the lack of information about the corona virus vaccine (Covid-19) from the Bamboo Curtain country could be a problem.
In a joint dialogue with the Antlantic Council, he warned that the efficacy of some vaccines, he cited Sinopharm and Sinovac, was unknown. Because absolutely no detailed information about the experiment was shared.
“This means that in the medium-long term it is almost certain that if the vaccine is not right, it will facilitate the emergence of new variants, which in no way will improve the situation of these countries,” he said as written by AFP, Thursday (4/2/2021).
Macron’s statement followed a day earlier, European Commission Chair Ursula von der Leyen urged China and Russia to show all data on their vaccine studies. Moreover, if the two countries want their vaccines to be approved in the European Union (EU).
Last Friday, Macron also had doubts about the British-Swedish vaccine AstraZeneca. He doubts the vaccine is effective for ages 65 and over, even though European regulators approve its use for adults of all ages.
France itself has been disappointed with the UK’s Sanofi-GalxoSminthKline (GSK) vaccine and their leading research center, the Pasteur Institute. There has been a setback in vaccine development efforts, after reports of low efficacy in the elderly cohort.
The ‘hunt’ for the Covid-19 vaccine has led many countries to compete to design and distribute vaccines worldwide. Observers think this is also a way to increase political, economic and prestige influence.
In Europe, China’s Sinopharm vaccine, for example, will be used in Hungary and Serbia. Previously, the Chinese vaccine was also used by a number of countries ranging from Turkey, Pakistan, United Arab Emirates, West African countries including Indonesia.
Earlier in December, Sinopharm said the vaccine’s efficacy rate reached 79.34%. However this is lower than the trial in the UAE, which was announced earlier at 86%.
Meanwhile, Sinovac, in a preliminary level test in Turkey showed an efficacy of 91.25%. In RI the efficacy is 65.3% and in Brazil the efficacy is 50.4%.
(boss / boss)
– .
